Acetic acid (2S,3R,4S,5R,6R)-4,5-diacetoxy-6-acetoxymethyl-2-((1R,2S,3R)-3-ethynyl-2,3,5,12-tetrahydroxy-2-methyl-6,11-dioxo-1,2,3,4,6,11-hexahydro-naphthacen-1-yloxy)-tetrahydro-pyran-3-yl ester | 730991-03-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 蒽环类药物
• 英文名称: Acetic acid (2S,3R,4S,5R,6R)-4,5-diacetoxy-6-acetoxymethyl-2-((1R,2S,3R)-3-ethynyl-2,3,5,12-tetrahydroxy-2-methyl-6,11-dioxo-1,2,3,4,6,11-hexahydro-naphthacen-1-yloxy)-tetrahydro-pyran-3-yl ester
• CAS: 730991-03-4
• 化学式: C₃₅H₃₄O₁₆
• 分子量: 710.645
• InChiKey: LJZRNEHXLPFEOG-INLMFRHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.69
• 重原子数：
  51.0
• 可旋转键数：
  7.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  238.72
• 氢给体数：
  4.0
• 氢受体数：
  16.0

反应信息

• 作为反应物：
  描述：

  Acetic acid (2S,3R,4S,5R,6R)-4,5-diacetoxy-6-acetoxymethyl-2-((1R,2S,3R)-3-ethynyl-2,3,5,12-tetrahydroxy-2-methyl-6,11-dioxo-1,2,3,4,6,11-hexahydro-naphthacen-1-yloxy)-tetrahydro-pyran-3-yl ester 在 盐酸 、 硫酸 、 mercury(II) oxide 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 25.5h， 生成 (+)-8-hydroxy-8-methylidarubicinone
  参考文献：
  名称：

  Enantioselective synthesis of (+)-8-hydroxy-8-methylidarubicinone

  摘要：

  An asymmetric Diels-Alder reaction methodology was employed to construct the tetracyclic structure of the anthra-cyclinone. A five-step sequence was needed to furnish the target (+)-8-hydroxy-8-methylidarubicinone. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.03.047
• 作为产物：
  描述：

  (E)-2-methyl-1-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyloxy)-3-trimethylsiloxybuta-1,3-diene 在 lead(IV) acetate 、 二甲基二环氧乙烷 、 溶剂黄146 、 锌 作用下， 以 四氢呋喃 、 二氯甲烷 、 丙酮 、 乙腈 为溶剂， 反应 17.0h， 生成 Acetic acid (2S,3R,4S,5R,6R)-4,5-diacetoxy-6-acetoxymethyl-2-((1R,2S,3R)-3-ethynyl-2,3,5,12-tetrahydroxy-2-methyl-6,11-dioxo-1,2,3,4,6,11-hexahydro-naphthacen-1-yloxy)-tetrahydro-pyran-3-yl ester
  参考文献：
  名称：

  Enantioselective synthesis of (+)-8-hydroxy-8-methylidarubicinone

  摘要：

  An asymmetric Diels-Alder reaction methodology was employed to construct the tetracyclic structure of the anthra-cyclinone. A five-step sequence was needed to furnish the target (+)-8-hydroxy-8-methylidarubicinone. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.03.047